Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $137,212 - $213,624
9,697 Added 49.51%
29,282 $554,000
Q1 2023

May 15, 2023

SELL
$10.48 - $16.94 $180,245 - $291,351
-17,199 Reduced 46.76%
19,585 $298,000
Q4 2022

Feb 14, 2023

BUY
$5.52 - $12.73 $203,047 - $468,260
36,784 New
36,784 $468,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $509M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Endurant Capital Management LP Portfolio

Follow Endurant Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.